AstraZeneca (AZN) Tops Q2 EPS by 17c

Earlier, AstraZeneca (NYSE: AZN) reported Q2 EPS of $1.53, $0.17 better than the analyst estimate of $1.36. Revenue for the quarter came in at $6.66 billion versus the consensus estimate of $6.78 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Evercore cuts HPE rating amid 'tougher setup'
• Akebia doses first patient in Phase 2 kidney disease trial
• Addus HomeCare to acquire AccentCare personal care unit for $275M